These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 8111812)

  • 21. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacoeconomics and formulary decision making.
    Sanchez LA
    Pharmacoeconomics; 1996; 9 Suppl 1():16-25. PubMed ID: 10160112
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The military health services system model for pharmacoeconomic decision making.
    Ries AJ; Potyk RP; Brier KL; Miller MR; Tornow JJ; Weber MP; Finder SF; Reeves CS
    Med Interface; 1995 May; 8(5):132-7. PubMed ID: 10142786
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ontario's formulary committee: how recommendations are made.
    PausJenssen AM; Singer PA; Detsky AS
    Pharmacoeconomics; 2003; 21(4):285-94. PubMed ID: 12600223
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incorporating quality of life data into managed care formulary decisions: a case study with salmeterol.
    Bukstein DA
    Am J Manag Care; 1997 Nov; 3(11):1701-6. PubMed ID: 10178468
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of a pharmaceutical risk sharing agreement based on the purchaser's total budget.
    Zaric GS; O'brien BJ
    Health Econ; 2005 Aug; 14(8):793-803. PubMed ID: 15685669
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacy formularies in integrated health systems.
    Osborne JA
    J Healthc Resour Manag; 1997; 15(1):18-20. PubMed ID: 10164678
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The arrival of economic evidence in managed care formulary decisions: the unsolicited request process.
    Neumann PJ
    Med Care; 2005 Jul; 43(7 Suppl):27-32. PubMed ID: 16056006
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Showing outcomes and proving value brings success.
    Fullerton DS; Atherly D; Sullivan SD
    Manag Care Interface; 2001 Jun; 14(6):63-5, 71. PubMed ID: 11432153
    [TBL] [Abstract][Full Text] [Related]  

  • 30. AMCP Format dossier requests: manufacturer response and formulary implications for one large health plan.
    Spooner JJ; Gandhi PK; Connelly SB
    J Manag Care Pharm; 2007; 13(1):37-43. PubMed ID: 17269835
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Do drug formulary policies reflect evidence of value?
    Neumann PJ; Lin PJ; Greenberg D; Berger M; Teutsch S; Mansley E; Weinstein MC; Rosen AB
    Am J Manag Care; 2006 Jan; 12(1):30-6. PubMed ID: 16402886
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The use of pharmacoeconomic data in formulary selection.
    Hatoum HT; Freeman RA
    Top Hosp Pharm Manage; 1994 Jan; 13(4):47-53. PubMed ID: 10130683
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Pharmaco-economic evaluations of new drugs: potential key to a more efficient allocation of the health care budget].
    Delwel GO; Sprenger MJ
    Ned Tijdschr Geneeskd; 2002 Jun; 146(23):1068-71. PubMed ID: 12085554
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Update and evaluation of Australian guidelines. Industry perspective.
    Carmine B
    Med Care; 1996 Dec; 34(12 Suppl):DS226-32. PubMed ID: 8969330
    [No Abstract]   [Full Text] [Related]  

  • 36. The evolving use of cost-effectiveness analysis in formulary management within the Department of Veterans Affairs.
    Aspinall SL; Good CB; Glassman PA; Valentino MA
    Med Care; 2005 Jul; 43(7 Suppl):20-6. PubMed ID: 16056005
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Global formulary review: how do we integrate pharmacogenomic information?
    Poppe LB; Roederer MW
    Ann Pharmacother; 2011 Apr; 45(4):532-8. PubMed ID: 21487085
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Application of pharmacoeconomics to formulary management in a health system setting.
    Studdert AL; Gong CL; Srinivas S; Chin AL; Deresinski S
    Am J Health Syst Pharm; 2019 Feb; 76(6):381-386. PubMed ID: 31361838
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Institutional formularies: the relevance of pharmacoeconomic analysis to formulary decisions.
    Lipsy RJ
    Pharmacoeconomics; 1992 Apr; 1(4):265-81. PubMed ID: 10147017
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Economic analysis as an aid to subsidisation decisions: the development of Australian guidelines for pharmaceuticals.
    Henry D
    Pharmacoeconomics; 1992 Jan; 1(1):54-67. PubMed ID: 10147039
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.